Maverick Ventures
SelectiveFiled to raiseDallas, TXBiotechnology, Healthcare, Healthcare ServicesLast fund filed 2025
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Maverick Silicon Fund | 2025 | Indefinite | $813M | 155 |
| Maverick Ventures Cycle 4 Serial Fund | February 2024 | $103M | $103M | 37 |
| Maverick HP | June 2023 | Indefinite | $786M | 1 |
| Maverick Growth CIFiled to raise in 2021, with no closing reported yet. | 2021 | Indefinite | $0 | 0 |
| Maverick Growth |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
11 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David SingerNot on the current fund | Slowing | Healthcare services, Biotech & pharma, Medical devices | 9 |
Classified sectors of Maverick Ventures’s own portfolio companies, based on 4 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Maverick Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Aisling Capital | 1 | UPTAKE MEDICAL |
| Benchmark | 1 | 1Life Healthcare |
| Kendall Capital Partners | 1 | Seer Biosciences |
| Polaris Partners | 1 |
| 2021 |
| Indefinite |
| $0 |
| 0 |
| Maverick USA | 2021 | Indefinite | $1.6B | 175 |
| Maverick QM Neutral | September 2018 | Indefinite | $39M | 3 |
| Maverick Ventures Investment Fund | 2018 | $117M | $130M | 38 |
| Maverick Advisors Fund | 2018 | $118M | $117M | 27 |
| Maverick Fundamental Quant Neutral | 2018 | Indefinite | $1.1B | 147 |
| Maverick QES Long Fund | December 2014 | Indefinite | $25M | 2 |
| Maverick Fundamental Quant | December 2014 | Indefinite | $148M | 37 |
| Maverick Select | July 2012 | Indefinite | $322M | 66 |
| MAVERICK SEED PARTNERS | July 2011 | Indefinite | $129M | 19 |
| MAVERICK LONG ENHANCED | April 2008 | Indefinite | $1.5B | 65 |
| MAVERICK LONG | April 2005 | Indefinite | $602M | 88 |
| MAVERICK STABLE PARTNERS | July 2002 | Indefinite | $1.1B | 438 |
| MAVERICK LEVERED PARTNERS L P | July 1998 | Indefinite | $1B | 692 |
| MAVERICK FUND USA | October 1993 | Indefinite | $5B | 1,004 |
| 1 |
| Lee Ainslie III | Slowing | None listed | 1 | 1 |
| David BrosgolNot on the current fund | Quiet | None listed | 1 | 0 |
| John McCaffertyNot on the current fund | Quiet | None listed | 0 | 0 |
| Keith HenningtonNot on the current fund | Quiet | None listed | 0 | 0 |
| Sam EllisNot on the current fund | Quiet | None listed | 2 | 0 |
| Sophia DilbertNot on the current fund | Quiet | None listed | 0 | 0 |
| Suzanne Guthrie | Quiet | None listed | 0 | 0 |
| Trevor Wiessmann | Quiet | None listed | 0 | 0 |
| W. HenningtonNot on the current fund | Quiet | None listed | 0 | 0 |
| Wiessmann TrevorNot on the current fund | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Seer Biosciences |
A shared board seat: a company where filings name a Maverick Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.